
    
      Study duration per participant will be approximately 30 days including: 1 day of screening
      and vaccination, a phone call and a safety-follow up/end of study visit at Day 8 and Day 30
      after vaccine administration, respectively.

      Safety assessment includes solicited reactions within 7 days after vaccination, unsolicited
      adverse events (AEs) up to 30 days after vaccination, serious adverse events (SAEs) and
      adverse event of special interest (AESI) throughout the study.
    
  